This site is intended for health professionals only!

Drugs relieve pain from migraine

teaser

Migraine sufferers could in future benefit from drugs that target a peptide which is released in the brain during a migraine.

Writing in The Lancet, Dr Stephen Silberstein, of Thomas Jefferson University in the US, reports that olcegepant – an intravenous drug that targets gene-related peptide (CGRP) – has been shown to relieve migraine pain by 66% compared with 27% for placebo.

Meanwhile, another CGRP drug, telcagepant, was as effective at reducing pain as the conventional migraine treatment zolmitriptan.

Dr Silberstein commented: “Telcagepant was effective and generally well tolerated for acute migraine treatment.

“Phase III trials are positive with results similar to those with zolmitriptan and an adverse-event profile similar to that for placebo and lower than that with zolmitriptan.”

Migraine with aura – sensory phenomena that occur before the migraine itself, such as visual flashes – roughly doubles the risk of heart attack, increases the risk of angina by 71%, and more than doubles the risk of death from ischaemic cardiovascular disease.

People with migraine also have an increased risk of having a poor cholesterol profile and high blood pressure, and a parental history of early heart attack.

Copyright PA Business 2008

The Lancet



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: